How long do patients with acute myeloid leukemia (AML) M5 typically survive?

Diseases caused by abnormalities in hematopoietic stem cells primarily involve uncontrolled proliferation of malignant cells, suppression of normal cellular proliferation, dysregulated apoptosis, and impaired growth of normal bone marrow hematopoietic cells. So, how long do patients with acute monocytic leukemia (AML-M5) typically survive?

How long do patients with AML-M5 typically survive?

Patients with AML-M5 typically survive only about six months. AML-M5, also known as acute monocytic leukemia or M5-type acute myeloid leukemia, is highly aggressive. Without timely and intensive chemotherapy, the leukemic cells proliferate extensively within the bone marrow, severely suppressing normal hematopoiesis. This leads to pancytopenia—reduced levels of red blood cells, white blood cells, and platelets—predisposing patients to life-threatening complications such as infection, hemorrhage, and anemia.

Such patients are at high risk for severe complications including septic shock, hypovolemic shock, and cardiac dysfunction. However, with prompt and aggressive clinical treatment—particularly when followed by timely hematopoietic stem cell transplantation—patients can achieve long-term survival. Stem cell transplantation helps restore normal hematopoietic and immune function, potentially leading to clinical cure and sustained remission.

In daily life, patients should maintain a balanced routine—avoiding overexertion, staying warm, and refraining from staying up late. Such lifestyle measures help preserve immune function and enhance resistance against pathogenic microorganisms, thereby reducing the risk of developing leukemia. We hope this information is helpful to you!